| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.019 | 0.8 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | birinapant | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.8 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.8 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | 0.021 | 0.8 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.8 |